Today's Drugs
With the help of expert contributors we print in this section notes on drugs in common use
Steroid Drugs in Chest Disease
Steroid drugs have been used in the treatment of a number of chest diseases. Though the complications of long-term treatment are well recognized,' if properly used these drugs may be valuable in treating several conditions.
Asthma INTRAVENOUS STEROIDS
The most important use of steroids in chest disease is in the treatment of asthma. This disease may present with different degrees of severity. The most serious form is status asthmaticus and in this condition the use of intravenous steroids is mandatory. The best preparation to use is probably hydrocortisone hemisuccinate, since this is a water-soluble ester which may be given by rapid intravenous injection. This route is desirable for two reasons: firstly, to achieve a high blood level as quickly as possible; and, secondly, because we are becoming increasingly aware that drug interactions or inactivation can occur when compounds are simply added to a slowly running drip-so that more use is being made of intravenous drugs given as single dose "slugs" into a drip. A regimen that is often effective is to give 30 mg of prednisone in divided doses on the first day and reduce by one 5-mg tablet a day over the next week. Such a six-day course will get many patients over an exacerbation. If it is the patient's first attack of asthma it may be possible then simply to stop the prednisone. A small proportion of patients may never need it again. Some will need several such courses of intermittent therapy, while others will need to take a permanent maintenance dose of the drug to render them reasonably free of dyspnoea and to prevent further attacks.
MAINTENANCE THERAPY
The group of patients on maintenance steroid therapy presents a problem. In general terms, if the maintenance dose can be kept at or below 19 mg a day of prednisone (or its equivalent in other steroids, though none of them are appreciably better in asthma) serious side effects are unlikely. Obvious side effects will occur in adults regularly taking more than 10 mg a day, or in children even on this dosage. These consist of some or all of the features of Cushing's syndrome. Endogenous steroid production is also suppressed, which may lead to retarded growth in children and also withdrawal symptoms when attempts are made to reduce the prednisone dosage.
Various methods have been made to avoid these disadvantages. As long ago as 1963 an alternative-day regimen was tried.4 In many patients this was found to be adequate to control the asthma with fewer side effects and less adrenal suppression. Since then several regimens have been tried, including taking the drug on three consecutive days of the week only. More recently5 it has been shown that such an intermittent regimen was no more effective than continuous daily treatment in preserving the response of the hypothalamo-pituitaryadrenal axis to stress. Another approach was to use corticotrophin (ACTH) or its newer synthetic derivatives. The logic behind this was that stimulating the patient's own adrenals to produce corticosteroids might be effective therapeutically with fewer side effects and, of course, no suppression. This method still does seem to have disadvantages as regards preventing stunting of growth in children.6 A disadvantage was that ACTH had to be administered by injection, which could be painful, though it was surprising how well some children tolerated this, even learning to inject themselves.
Newer synthetic varieties of ACTH are now available.
These are the tetracosactrin derivatives Cortrosyn Depot (Organon), and Synacthen Depot (Ciba). Both preparations are available in a strength of 1 mg per ml and have proved effective in doses varying from 0:5 mg once a week to 1 mg three times a week.7 A dose of 0-5 mg twice a week or 1 mg weekly would be a fairly typical one. The disadvantage of this is that patients may tend to relapse or feel "weak" the day or two days before the next dose is due, or may suffer from flushing attacks or headache in the 24 hours after injection. Moreover, such a regimen does not allow the "fine control" of asthma. A compromise has been effective in some patients-namely, to administer tetracosactrin once or twice weekly and give a small dose of prednisone (say, 2-5 mg) on the days when no injection is given. In fact, no rigid regimen can be laid down for any patient on long-term steroid therapy: one has to titrate the patient's asthma against the lowest dose of steroid that will keep him well. In this connexion the introduction of disodium cromoglycate has enabled many young patients with allergic asthma to reduce their maintenance steroid dosage, or to come off it altogether. A recent development has been the introduction of a steroid aerosol, beclomethasone diproprionate.8 This appears to offer the advantage of delivering a small regular dose to the lung and of avoiding systemic effects.
A final clinical point is to emphasize the importance of taking an adequate drug history from all asthmatics. Many proprietary steroid preparations bear names that in no way resemble "cortisone" or "prednisone," so that the doctor must be wary and find out if the patient has been receiving steroids, particularly if an anaesthetic and operation are contemplated. In the latter situation intramuscular steroids given on the morning and evening of the operation may provide useful cover if no infusion is set up. Hydrocortisone can always be given into a drip.
Sarcoidosis
Steroids have been extensively used in the treatment of pulmonary sarcoidosis. Initial reports were enthusiastic, but subsequent long-term assessment gave a different picture. They are now known to be of value in patients with severe impairment of lung function, but many milder cases improve spontaneously. In one study9 serial lung function tests were carried out in a group of 43 patients treated for one to six years. Steroids produced an improvement in twelve out of *thirteen patients with severely impaired lung function but were of doubtful value in the other cases. Other workers have had similar results. Steroids, however, may be essential to treat the renal or eye complications of sarcoidosis.
Fibrosing Alveolitis and Collagen Diseases
Fibrosing alveolitis may be associated with collagen diseases, such as scleroderma (systemic sclerosis), or may be cryptogenic. Patients in the latter category may respond to steroids if treated in the acute stage of their illness. In a recent study10 it was shown that patients treated within three months of the appearance of symptoms could respond dramatically. Prednisone was much less effective in the chronic form of the disease, which is the more common variety. In this series, and in others, azathioprine (Imuran) seemed beneficial in some cases.
When the fibrosing alveolitis is associated with an overt collagen disease the response tends not to be so good. In polyarteritis nodosa airways obstruction occurs and some patients present with asthma. Some of these cases respond dramatically. In the treatment of all these conditions, and in sarcoidosis one can start treatment with 30-45 mg of prednisone a day for one to two weeks and then drop the dosage quite rapidly to a maintenance dosage of 10 mg a day. Ampicillin has been shown in dogs and guinea pigs, but not humans, to relax the ureter. However, the authors' conclude it to be unlikely that ampicillin can interfere with the mechanism of normal micturition. I know of no evidence that ampicillin affects control of the bladder.
1 Benzie, G., Bermudez, E., Arrigoni. E., and Berte, F., Arch:ves Intrnationales de Pharmacodynamie et de Therapie, 1970, 183, 159.
Gastric Fibrosis Inheritance
Of three sisters, the eldest has two of four children (all boys) with cystic fibrosis, and the second has a normal girl, and a boy with cystic fibrosis. The youngest sister, aged 20, is newly married. and is worried about the chances of producing affected offspring. A married brother has two normal ch-ldren. There is no other known family history.
The chance that the younger sister carries the gene for cystic fibrosis is two in three. The chance that her husband is a carrier is about one in 20. Accordingly the chance of any particular child of theirs having cystic fibrosis is 2
x 0 xa little less than 1%.
